They observed previously unknown somatic mutations in the MAPK1 gene, inactivating mutations in the HLA-B gene, and mutations in EP300, FBXW7, NFE2L2, TP53 and ERBB2 in squamous cell carcinoma samples, and somatic ELF3 and CBFB mutations in adenocarcinomas. This evidence concerns the gene EP300 and squamous cell carcinoma.